Found 141 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is an umbrella research study is designed to learn more about the safety and effectiveness of AMG 510 in combination with different investigational agents. Eligible subjects include adults with KRAS p.G12C Mutation.
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) after surgery for colon cancer.This study is Enrolling by Invitation only at Lancaster General Health - ABBCI.
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. We would like to rely on Advarra as the IRB of record for this study.
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2.2.1 (Primary Endpoints) Please see the Protocol, Section 2.2.2 (Secondary Endpoints)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. We would like to rely on Advarra as the IRB …
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. We would like to rely on CIRB as the IRB of record for this study.
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors. We would like to rely on Advarra as the IRB of record for this study.
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …
